

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Havelund et al.

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: September 17, 1999

Examiner: To Be Assigned

For: Acylated Insulin



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were filed with USSN 08/975,365 filed on April 21, 1998, July 13, 1998 and April 1, 1999, the benefit of which is claimed under 35 USC 120.


Brance and Langkjaer, Chemical Stability of Insulin, Acta Pharm., No. 11, 163-149, 158 (1992)

4. MIMS Annual 1991, Section 6d "Insulin Preparations" (IMS Publishing).
5. MIMS Annual 1993, Section 6d "Insulin Preparations" (IMS Publishing).
6. Prescription Products Guide 1992, pages 942-944, 957-958 and 1307-1308.
7. J. Schlichtkrull, "Insulin Crystals" (Ejnar Munksgaard) 1958, pages 21-33.2
8. A Marble et al., Joslin's Diabetes Mellitus, 12th Edition, 1985, pages 380-382.
9. Schade: Intensive Insulin Therapy, Excerpta Medica 1983, pages 7 and 304.
10. W.O. Foye: Principles of Medicinal Chemistry 1974, pages 563-565.
11. Doerge: Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry 1982, pages 774-776.
12. Montague: Diabetes and the Endocrine Pancreas - A Biochemical Approach, 1983, pages 36 and 37.
13. U.S. Patent No. 3,528,960
14. WO 91/12817
15. JP 57-67548
16. GB 1 492 997
17. Samuel et al., (1978) Clin. Exp. Immunol. 33:252-260
18. Kurtz et al., (1983) Diabetologia 25:322-324

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: September 17, 1999



Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123